289 related articles for article (PubMed ID: 17434579)
1. Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma.
Giuntoli RL; Garrett-Mayer E; Bristow RE; Gostout BS
Gynecol Oncol; 2007 Jul; 106(1):82-8. PubMed ID: 17434579
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma.
Wu TI; Chang TC; Hsueh S; Hsu KH; Chou HH; Huang HJ; Lai CH
Gynecol Oncol; 2006 Jan; 100(1):166-72. PubMed ID: 16182349
[TBL] [Abstract][Full Text] [Related]
3. The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital.
Dinh TA; Oliva EA; Fuller AF; Lee H; Goodman A
Gynecol Oncol; 2004 Feb; 92(2):648-52. PubMed ID: 14766261
[TBL] [Abstract][Full Text] [Related]
4. Salvage cytoreductive surgery for recurrent endometrial cancer.
Bristow RE; Santillan A; Zahurak ML; Gardner GJ; Giuntoli RL; Armstrong DK
Gynecol Oncol; 2006 Oct; 103(1):281-7. PubMed ID: 16631236
[TBL] [Abstract][Full Text] [Related]
5. Treatment of uterine leiomyosarcoma.
Berchuck A; Rubin SC; Hoskins WJ; Saigo PE; Pierce VK; Lewis JL
Obstet Gynecol; 1988 Jun; 71(6 Pt 1):845-50. PubMed ID: 2453004
[TBL] [Abstract][Full Text] [Related]
6. Uterine papillary serous carcinoma: patterns of failure and survival.
Wang W; DO V; Hogg R; Wain G; Brand A; Bull C; Stenlake A; Gebski V
Aust N Z J Obstet Gynaecol; 2009 Aug; 49(4):419-25. PubMed ID: 19694700
[TBL] [Abstract][Full Text] [Related]
7. Leiomyosarcoma: One disease or distinct biologic entities based on site of origin?
Worhunsky DJ; Gupta M; Gholami S; Tran TB; Ganjoo KN; van de Rijn M; Visser BC; Norton JA; Poultsides GA
J Surg Oncol; 2015 Jun; 111(7):808-12. PubMed ID: 25920434
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki University Central Hospital 1990-2001.
Koivisto-Korander R; Butzow R; Koivisto AM; Leminen A
Gynecol Oncol; 2008 Oct; 111(1):74-81. PubMed ID: 18657852
[TBL] [Abstract][Full Text] [Related]
9. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).
Cheng X; Jiang R; Li ZT; Tang J; Cai SM; Zhang ZY; Tian WJ; Zang RY
Eur J Surg Oncol; 2009 Oct; 35(10):1105-8. PubMed ID: 19443175
[TBL] [Abstract][Full Text] [Related]
10. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer.
Santillan A; Karam AK; Li AJ; Giuntoli R; Gardner GJ; Cass I; Karlan BY; Bristow RE
Gynecol Oncol; 2007 Mar; 104(3):686-90. PubMed ID: 17141302
[TBL] [Abstract][Full Text] [Related]
11. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
Anticancer Res; 2003; 23(1B):729-32. PubMed ID: 12680175
[TBL] [Abstract][Full Text] [Related]
12. Leiomyosarcoma of the inferior vena cava: survival after aggressive management.
Ito H; Hornick JL; Bertagnolli MM; George S; Morgan JA; Baldini EH; Wagner AJ; Demetri GD; Raut CP
Ann Surg Oncol; 2007 Dec; 14(12):3534-41. PubMed ID: 17896156
[TBL] [Abstract][Full Text] [Related]
13. Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms.
Yan TD; Bijelic L; Sugarbaker PH
Ann Surg Oncol; 2007 Aug; 14(8):2289-99. PubMed ID: 17541772
[TBL] [Abstract][Full Text] [Related]
14. Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma.
Leitao MM; Brennan MF; Hensley M; Sonoda Y; Hummer A; Bhaskaran D; Venkatraman E; Alektiar K; Barakat RR
Gynecol Oncol; 2002 Dec; 87(3):287-94. PubMed ID: 12468327
[TBL] [Abstract][Full Text] [Related]
15. Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer.
Fotiou S; Aliki T; Petros Z; Ioanna S; Konstantinos V; Vasiliki M; George C
Gynecol Oncol; 2009 Aug; 114(2):178-82. PubMed ID: 19450872
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
Tebes SJ; Sayer RA; Palmer JM; Tebes CC; Martino MA; Hoffman MS
Gynecol Oncol; 2007 Sep; 106(3):482-7. PubMed ID: 17590420
[TBL] [Abstract][Full Text] [Related]
17. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
[TBL] [Abstract][Full Text] [Related]
18. Secondary cytoreductive surgery in recurrent uterine leiomyosarcoma: a multi-institutional study.
Bizzarri N; Ghirardi V; Di Fiore GLM; De Iaco P; Gadducci A; Casarin J; Perrone AM; Pasciuto T; Scambia G; Fagotti A
Int J Gynecol Cancer; 2019 Sep; 29(7):1134-1140. PubMed ID: 31420411
[TBL] [Abstract][Full Text] [Related]
19. Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome.
Bristow RE; Peiretti M; Gerardi M; Zanagnolo V; Ueda S; Diaz-Montes T; Giuntoli RL; Maggioni A
Gynecol Oncol; 2009 Aug; 114(2):173-7. PubMed ID: 19482344
[TBL] [Abstract][Full Text] [Related]
20. The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma.
Park JY; Park SK; Kim DY; Kim JH; Kim YM; Kim YT; Nam JH
Gynecol Oncol; 2011 Aug; 122(2):255-9. PubMed ID: 21565389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
